YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG: 1558)
Hong Kong
· Delayed Price · Currency is HKD
9.56
-0.10 (-1.04%)
Dec 31, 2024, 12:08 PM HKT
YiChang HEC ChangJiang Pharmaceutical Revenue
YiChang HEC ChangJiang Pharmaceutical had revenue of 2.45B CNY in the half year ending June 30, 2024, with 89.80% growth. This brings the company's revenue in the last twelve months to 5.54B, down -2.13% year-over-year. In the year 2023, YiChang HEC ChangJiang Pharmaceutical had annual revenue of 6.29B with 68.08% growth.
Revenue (ttm)
5.54B CNY
Revenue Growth
-2.13%
P/S Ratio
1.38
Revenue / Employee
1.20M CNY
Employees
4,618
Market Cap
8.21B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 6.29B | 2.55B | 68.08% |
Dec 31, 2022 | 3.74B | 2.83B | 309.83% |
Dec 31, 2021 | 913.79M | -1.43B | -61.08% |
Dec 31, 2020 | 2.35B | -3.88B | -62.27% |
Dec 31, 2019 | 6.22B | 3.71B | 147.92% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 26.04B |
Hansoh Pharmaceutical Group Company | 13.00B |
JD Health International | 58.84B |
WuXi Biologics | 18.39B |
Sinopharm Group | 634.32B |
Innovent Biologics | 8.01B |
Sino Biopharmaceutical | 29.86B |
CSPC Pharmaceutical Group | 33.53B |